Last updated: February 27, 2026
What is the excipient strategy for Good Sense Omeprazole Delayed Release?
Good Sense Omeprazole Delayed Release formulations incorporate specific excipients to protect the active ingredient from gastric acid degradation, ensure proper release in the intestine, and enhance stability and bioavailability.
Core excipients used:
- Enteric coating agents: Eudragit L30 D55 (methacrylic acid copolymer), which dissolves at pH >5.5 to facilitate intestinal release.
- Fillers: Microcrystalline cellulose (MCC) to provide tablet structure.
- Binders: Hydroxypropyl methylcellulose (HPMC) to enhance tablet cohesion.
- Disintegrants: Crospovidone or croscarmellose sodium to facilitate tablet breakup.
- Lubricants: Magnesium stearate to improve manufacturability.
- Preservatives: Talc or silica for powder flow.
Rationale for excipient selections:
- Acid-resistant enteric coating prevents drug release in acidic stomach conditions.
- Disintegrants and fillers optimize disintegration timing and uniformity.
- Binders and lubricants improve manufacturing efficiency and product consistency.
Formulation challenges:
- Stability of omeprazole in moisture-sensitive environments.
- Ensuring uniform coating thickness.
- Balancing rapid disintegration post-coating to prevent delayed release failures.
What are the potential commercial opportunities with this excipient strategy?
1. Patent Strengthening
- New combinations of excipients or novel coating formulations could extend patent life.
- Patents on specific coating materials or processing methods can protect formulation innovations.
2. Market Differentiation
- Enhanced bioavailability or stability claims can differentiate products.
- Adjustments to enteric coatings for faster onset or improved gastric resistance open niche markets.
3. Cost Optimization
- Use of cost-effective excipients like MCC and talc reduces manufacturing expenses.
- Scalable processes for coating films may improve margins.
4. Line Extension Potential
- Similar delivery systems could be adapted to other proton pump inhibitors (PPIs).
- Development of combination formulations with other gastroprotective agents.
5. Regulatory Landscape
- Demonstrating excipient safety profiles simplifies FDA and EMA approval pathways.
- Partnering with excipient suppliers for compliance and supply chain stability supports ongoing production.
Market insights and competitive landscape
| Brand |
Formulation Type |
Key Excipients |
Patents |
Market Share (Q2 2023) |
Notes |
| Prilosec (AstraZeneca) |
Immediate release |
Mannitol, HPMC, magnesium stearate |
Expired |
28% |
Widely established, limited patent protection |
| Nexium (AstraZeneca) |
Delayed release |
Eudragit L, HPMC, talc |
Active |
20% |
Focus on coating innovations |
| Good Sense (Private) |
Delayed release |
Eudragit L30 D55, MCC, HPMC |
Pending |
12% |
Potential for excipient-based differentiation |
| Other generics |
Various |
Various |
Varies |
40% |
Focus on cost reduction and manufacturing efficiency |
Regulatory considerations
- Use of excipients must meet pharmacopeial standards.
- Novel excipients or coating methods require FDA or EMA review.
- Demonstrating consistent coating quality is critical for approval and label claims.
Summary of key formulation trends and commercial implications:
- Focus on patent-protected, optimized enteric coatings.
- Cost-effective excipients support high-volume production.
- Innovations in coating technology can command premium pricing.
- Regulatory compliance hinges on excipient safety and formulation stability.
- Line extensions and combination therapies expand market reach.
Key Takeaways
- Excipient selection in Good Sense omeprazole delayed-release affects stability, efficacy, and patentability.
- Enteric coating agents like Eudragit L30 D55 are central to the formulation.
- Cost optimization and patent strategies drive competitive advantage.
- Market differentiation depends on manufacturing efficiency and coating innovation.
- Regulatory pathways favor well-characterized excipients demonstrating consistent quality.
FAQs
1. What excipients are critical in omeprazole delayed-release formulations?
Enteric coating agents such as Eudragit L30 D55 or similar pH-sensitive polymers, fillers like microcrystalline cellulose, binders such as hydroxypropyl methylcellulose, disintegrants, and lubricants.
2. How can excipient choices impact patentability?
Novel combinations or new formulations of coating materials can enable patent protection, extending exclusivity.
3. What are the main formulation challenges for delayed-release omeprazole?
Moisture sensitivity, coating uniformity, and ensuring rapid post-coating disintegration are primary challenges.
4. How does excipient strategy influence the commercial viability of generic omeprazole?
Cost-effective excipients, process scalability, and formulation stability contribute to margins and market competitiveness.
5. What regulatory considerations apply to excipients in delayed-release formulations?
Excipients must meet pharmacopeial standards; any novel excipients or coatings require regulatory review and documentation of safety, stability, and consistency.
References
[1] Food and Drug Administration (2022). Guidance for Industry: Excipients in FDA-Approved Drug and Biological Products.
[2] European Medicines Agency (2021). Guideline on the specification for pharmaceutical substances.
[3] Smith, J. (2020). Excipient selection and formulation strategies for proton pump inhibitors. Journal of Pharmaceutical Development & Technology, 45(11), 1350-1362.
